ScholarIQanswers from OpenAlex & ORCID
Jan H.M. Schellens
ResearcherPublications, citations & collaboration network
Jan H.M. Schellens is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jan H.M. Schellens have?
ScholarIQindexed works
Jan H.M. Schellens has 1,181 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jan H.M. Schellens have?
ScholarIQcitation count
Jan H.M. Schellens has 60,158 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jan H.M. Schellens?
ScholarIQh-index
Jan H.M. Schellens has an h-index of 112 in OpenAlex.
What is the i10-index of Jan H.M. Schellens?
ScholarIQi10-index
Jan H.M. Schellens has an i10-index of 752 in OpenAlex.
What is the ORCID of Jan H.M. Schellens?
ScholarIQorcid
The ORCID for Jan H.M. Schellens is on the source record.
What is the OpenAlex record for Jan H.M. Schellens?
ScholarIQopenalex
The OpenAlex for Jan H.M. Schellens is on the source record.
What are the most-cited papers on Jan H.M. Schellens?
ScholarIQmost cited works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, Fabrice André, Jean‐Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schüler, Ulka N. Vaishampayan, Howard A. Burris, Guangming Tian, Mario Campone, Zev A. Wainberg, Wan‐Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, François Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf